drugset
drugset / Trial / NCT03881735

Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation

NCT03881735 ↗

Phase 2 Withdrawn Roswell Park Cancer Institute Celgene Corporation · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This phase II trial studies how well enasidenib works in treating in patients with acute myeloid leukemia with an IDH2 gene mutation that has come back or has not responded to treatment. Enasidenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. In this study we are investing if enasidenib can be used as maintenance therapy post salvage induction chemotherapy.

Timeline

Start
2019-12-02
Primary completion
2021-11-19
Completion
2022-11-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Enasidenib Small molecule — Oral

Indications

acute myeloid leukemia